Phase 3 N=300 Feasibility of 5% Albumin Compared With Balanced Crystalloid, as Intravenous Fluid Resuscitation in Adult Patients With Sepsis, Presenting as an Emergency to Hospital
Sepsis
Primary: Recruitment Rate — 150; 150 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=609 STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction
Myocardial Infarction
Primary: Successful Reperfusion — 305; 149 Participants — p=0.05
Phase 1 N=12 A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.
Healthy
Primary: Maximum Observed Concentration (Cmax) of PF-07817883 — 4030; 4985 ng/mL
Phase 1 N=36 A Study of Donanemab (LY3002813) in Healthy Chinese Participants
Healthy
Primary: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to…
N/A N=4,939 Improving Health and Employment Outcomes Through Workplace Opioid Policies
Opioid-Related Disorders
Primary: Proportion of Workers With Opioid Misuse, Opioid Use Disorder and Opioid Overdose: Administrative Data [Primary Outcome]
Phase 1 N=42 A Study of Donanemab (LY3002813) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Four Weeks (AUC[0-4 Weeks]) of Donanemab (i.e) Period 2, Period 4, Period 6…
N/A N=560 Efficacy of a Couple-Focused mHealth Symptom Self-management Program
Prostate Cancer
Primary: Change in Quality of Life Over Time as Assessed by Functional Assessment of Cancer Treatment (FACT-G) Scores — 89.48; 90.54; 90.29; 90.42 score on a scale — p=0.19
N/A N=55 CTAG Dissection/Trauma Post Marketing Surveillance Japan
Thoracic Aortic Aneurysm · Thoracic Aorta Injury · Thoracic Aortic Dissection
Primary: Primary Entry Tear Exclusion — 21; 26; 27; 22 Participants
N/A N=19 Feasibility of Pain Informed Movement for Knee OA
Knee Osteoarthritis
Primary: Acceptability of Content — 13 Participants
Phase 2 N=30 A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 4; 7; 7; 8 Participants
N/A N=19 Hepatitis A Vaccine Dosing Regimens Among Pediatric Patients on Immunosuppressive Therapy
Autoimmune Rheumatologic Disease
Primary: Hepatitis A Antibodies Titre — 9.4; 9.0; 394.7; 810.6 IU/L
Phase 2 N=34 A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly
Acromegaly
Primary: Percent Change in Insulin-like Growth Factor I (IGF-1) From Baseline to Week 27 — -6.20; -7.16; -7.09 Percent change
Phase 1 N=46 EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Rhabdoid Tumors · INI1-negative Tumors · Synovial Sarcoma
Primary: Recommended Phase 2 Dose (RP2D) (Dose Escalation Only) — 1200; 520 mg/m^2 BID
N/A N=150 Reducing Prehospital Medication Errors & Time to Drug Delivery by EMS During Simulated Pediatric CPR
Cardiopulmonary Arrest · Resuscitation · Pediatrics
Primary: Medication Dosage Errors — 5.7; 62.8 percentage of medication errors
Phase 3 N=158 Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
Bladder Cancer
Primary: Number of Patients With Histology-confirmed Lesions (Ta, T1, or CIS) Who Have at Least One Such Lesion Found by Hexvix Blue Light Cystoscopy But Not by White Light…